west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "溶血性贫血" 5 results
  • 心脏瓣膜手术后并发溶血性贫血的治疗

    目的 探讨心脏瓣膜手术后并发溶血性贫血的外科治疗方法及效果。方法 1998年1月至2007年12月,广东省人民医院广东省心血管病研究所共治疗11例心瓣膜手术后并发溶血性贫血患者,男9例,女2例;年龄15~57岁(40±14岁)。风湿性心瓣膜病6例,退行性心瓣膜病2例,先天性心瓣膜病2例,感染性心内膜炎1例。第一次手术:行二尖瓣置换术(MVR)2例,双瓣膜置换术(DVR)4例,二尖瓣人工瓣环成形术5例。第二次入院血红蛋白55~92 g/L(76±14 g/L),红细胞压积0.19~0.31(0.25±0.04),网织红细胞百分比0.08~0.17(0.12±0.04),总胆红素34.70~91.50 μmol/L(56.00±19.10 μmol/L),非结合胆红素23.40~54.90 μmol/L(38.60±12.30 μmol/L)。所有患者均先给予内科治疗,10例患者经内科治疗无效后再次行心瓣膜置换术或心瓣膜成形术治疗,另1例给予内科保守治疗。结果 再次手术治疗10例,术后死亡1例,死于溶血性贫血、肾功能衰竭和多器官功能衰竭;其他9例经再次手术治疗后痊愈出院,贫血症状消失,血常规检查正常。内科保守治疗治愈1例。随访10例,随访时间2个月至11年,心功能Ⅰ级8例,Ⅱ级2例,无晚期死亡。1例感染性心内膜炎患者出院时仍有轻度肾功能不全,随访3个月时肾功能完全恢复正常,随访1年心功能良好,无溶血症状。 结论 心瓣膜手术后并发溶血性贫血,如经内科治疗无效应尽早行再次心瓣膜手术治疗,可获得良好的效果。

    Release date:2016-08-30 05:56 Export PDF Favorites Scan
  • ACUTE HEMOLYTIC ANEMIA AFTER LIVER TRANSPLANTATION IN ONE CASE

    【Abstract】 Objective To report 1 case of acute hemolytic anemia after liver transplantation because of ABO compatibility and therapeutic experience. Methods The patient with liver cancer underwent orthotopic piggyback liver transplantation on September 2010 after radiofrequency ablation of the tumors. The donor and recipient ABO blood types were type O and type A, separately. Acute hemolytic anemia occurred at 10 days after transplantation and hemoglobin decreased to 56 g/L. The bone marrow showed active hyperplasia; and myeboid∶erythroid was 0.52∶1. The immunosuppressants were used and type O washed red blood cells were transfused immediately. Results The general condition of the patient was improved; hemoglobin increased gradually and returned to 111 g/L at 34 days after liver transplantation. At 12 months of follow-up, hemoglobin was within normal range. Conclusion Using graft blood type washed red blood cells transfusion and immunosuppressants could be an effective therapeutic procedure in the patient with ABO compatility graft when acute hemolytic anemia occurrs.

    Release date:2016-08-31 04:22 Export PDF Favorites Scan
  • A case report of pulmonary tumor thrombotic microangiopathy and review of the literature

    ObjectiveTo investigate the clinical features, diagnosis, treatment and prognosis of pulmonary tumor thrombotic microangiopathy (PTTM).MethodsA patient with PTTM was reported. Literatures about PTTM searched by WanFang databases and PubMed were reviewed for its clinical characteristics.ResultsA 62-year-old female was admitted with chief complaint of dry cough, dyspnea and hemoptysis. Progressive dyspnea, pulmonary hypertension and hypoxemia occurred during hospitalization. Computed tomography angiography (CTA) of the lung excluded pulmonary embolism. Peripheral blood appearing a large number of late erythroblasts and erythrocyte debris and progressively decreasing platelets suggested that the patient suffer from thrombotic microvascular disease. CT showed widely metastatic lesions at the vertebrae and sternum. On the basis of above clinical characteristics, PTTM was diagnosed clinically. Although the patient accepted respiratory support therapy, anticoagulation therapy and resuscitation, she still died 5 days later after hospitalization. Literatures about PTTM with complete clinical information were reviewed. A total of 92 PTTM cases were reviewed and the main reasons of these patients admitted were progressive dyspnea and chronic cough. During hospitalization, they all suffered varying degrees of hypoxia, while radiological findings of the lungs lack specificity. No abnormal sighs were found by lung CTA. The results of ultrasonic cardiography or the Swan–Ganz catheter indicated varying degrees of pulmonary hypertension, some patients were proved with disseminated intravascular coagulation and/or microangiopathic hemolytic anemia. The definite diagnosis of PTTM depended on the histologic evidence which were often obtained from post-mortem examination, because many patients couldn’t tolerate the lung biopsy due to rapid aggravation. The treatment of PTTM included respiratory support therapy, anticoagulation therapy, antipulmonary hypertension and the chemotherapy of primary or metastatic tumour. The prognosis of PTTM was poor and almost all of the patients died in a short term, ranged from 48 hours to 3 months.ConclusionIf a patient with a history of cancer or evidence of cancer metastasis has hypoxemia and pulmonary hypertension but without abnormal lung CTA signs, PTTM should be considered.

    Release date:2018-05-28 09:22 Export PDF Favorites Scan
  • 含呋喃唑酮与四环素四联疗法根除幽门螺杆菌致急性溶血性贫血一例

    Release date:2020-03-25 09:12 Export PDF Favorites Scan
  • Progression of CD20 monoclonal antibody in the treatment of autoimmune hemolytic anemia

    Autoimmune hemolytic anemia (AIHA) is an autoimmune disease in which the life span of red blood cells is shortened by red blood cell autoantibodies. Due to immune intolerance and abnormal immune regulation, the hyperfunction of B lymphocytes produces too many red blood cell autoantibodies. Anti-CD20 monoclonal antibody is a second-line drug for warm antibody AIHA and first-line drug for cold antibody AIHA by reducing B lymphocytes. At present, the optimal dose of anti-CD20 monoclonal antibody in the treatment of AIHA has not been determined. There are no reports on the treatment of primary AIHA with second- or third-generation anti-CD20 monoclonal antibodies.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content